Until recently, a patient could not receive an Alzheimer’s diagnosis without an expensive scan or invasive procedure. Last year, the Food and Drug Administration (FDA) cleared two blood-based biomarker tests—or BBB—that require only a routine blood sample for use in diagnosing Alzheimer’s disease. This is an important step forward in Alzheimer’s care, but it won’t… Â
